EGFR and non-small cell lung carcinoma: To evaluate the clinical performance of the HiCASE assay, 140 plasma samples obtained from NSCLC patients and healthy donors were included to detect EGFR mutations using three different approaches, namely HiCASE, ddPCR, and Super-ARMS assays.